<p>Company bets that AI-assisted analysis and a leaner trial design can get PrimeC to patients years sooner than the usual approval path. Most people diagnosed with ALS don’t live past three years. Most drugs aiming to treat it spend longer than that just getting through a single confirmatory trial. Th</p>